-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
MEK inhibitors (MEKi) have shown clinical efficacy in NRAS-mutated metastatic melanoma in randomized controlled trials, but their clinical use is currently limited to advanced, pretreated patients, in contrast to previous trials.
The situation is different
.
There are currently few data on the efficacy of MEK inhibitors in real clinical settings
This study is a retrospective, multicenter study evaluating the clinical course of melanoma patients (who had received at least one prior therapy) treated with MEK inhibitors at five German cancer centers
.
The primary endpoint was response rate
The clinical course of melanoma patients (who had received at least one prior therapy) treated with MEK inhibitors at five German cancer centers was assessed
A total of 33 patients were recruited, including 19 males (58%) and 14 females (42%), with a median age of 64 years
.
91% of patients were previously treated with immune checkpoint inhibitors, 90% had elevated serum lactate dehydrogenase (LDH) levels at the start of treatment, 33% had developed brain metastases, and 30% had ECOG Performance status ≥ 2 points
progression free survival
After a median follow-up of 10.
0 months, the overall response rate was 18.
2% (all partial responses), and the disease control rate was 48.
5%
.
The median duration of response was 6.
10.
overall survival
82% of patients experienced adverse events
.
The most common was acneiform rash (55%), followed by peripheral edema (33%)
In conclusion, the real clinical efficacy of MEK inhibitors in patients with NRAS-mutated advanced melanoma is comparable to that in clinical trials
True clinical efficacy of MEK inhibitors in patients with NRAS-mutated advanced melanoma and comparable in clinical trials True clinical efficacy of MEK inhibitors in patients with NRAS-mutated advanced melanoma and comparable in clinical trials
Original source:
Original source:Salzmann Martin,Pawlowski Johannes,Loquai Carmen et al.
leave a message here
